Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Gemcitabine-based Chemo in Chinese Advanced BTC
NCT05924880Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in biliary tract cancer (BTC), sponsored by AstraZeneca. Started Jul 2023; status: completed.
02
Drugs
durvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05924880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924880.